Nano-X Imaging Ltd. (NASDAQ:NNOX) Q3 2024 Earnings Conference Call November 21, 2024 8:30 AM ET

Company Participants

Mike Cavanaugh - IR
Erez Meltzer - CEO
Ran Daniel - CFO

Conference Call Participants

Ross Osborn - Cantor Fitzgerald
Jeffrey Cohen - Ladenburg
Scott Henry - Alliance Global

Operator

Ladies and gentlemen, thank you for standing by. Welcome to the Nano-X Third Quarter 2024 Earnings Call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.

I would like now to turn the conference over to Mike Cavanaugh, Investor Relations. Sir, please go ahead.

Mike Cavanaugh

Good morning, and thank you for joining us today. Earlier today Nano-X Imaging Limited released financial results for the quarter ended September 30, 2024. The release is currently available on the Investors section of the company's website. With me today are, Erez Meltzer, Chief Executive Officer and Acting Chairman; and Ran Daniel, Chief Financial Officer.

Before we get started, I would like to remind everyone that management will be making statements during this call that include forward-looking statements regarding the company's financial results, research and development, manufacturing and commercialization activities, regulatory process operations and other matters.

These statements are subject to risks, uncertainties, and assumptions that are based on management's current expectations as of today and may not be updated in the future. Therefore, these statements should not be relied upon as representing the company's views as of any subsequent date. Factors that may cause such a difference include, but are not limited to those described in the company's filings with the Securities and Exchange Commission.

We will also refer to certain non-GAAP financial measures to provide additional information to investors. A reconciliation of the non-GAAP to GAAP measures is provided with our press release, with the primary differences being non-GAAP net loss attributable to ordinary shares, non-GAAP cost of revenue, non-GAAP gross profit, non-GAAP gross profit margin, non-GAAP research and development expenses, non-GAAP sales and marketing expenses, non-GAAP general and administrative expenses, and non-GAAP gross loss per share.

With that, I'd now like to turn the call over to Erez Meltzer.

Erez Meltzer

Thank you for joining us today for our financial results call. I'm happy to share the progress, we have made deploying our innovative Nanox.ARC technology, as well as further progress with Nanox.AI, and the other components of the full Nanox solutions. Since its commercial deployment at the beginning of this year, there are now 47 units, almost 50 that are in various stages of shipments and deployments, for both commercial and clinical use.